Coronavirus: Commission continues expanding future vaccines portfolio with new talks
The European Commission yesterday concluded exploratory talks with CureVac to purchase a potential vaccine against COVID-19. This is following the positive steps with Sanofi-GSK on 31 July and Johnson & Johnson on 13 August and the signature of an Advance Purchase Agreement with AstraZeneca on 14 August.
The envisaged contract with CureVac would provide for the possibility for all EU Member States to purchase the vaccine, as well as to donate to lower and middle income countries or re-direct to European countries. It is anticipated that the Commission will have a contractual framework in place for the initial purchase of 225 million doses on behalf of all EU Member States, to be supplied once a vaccine has proven to be safe and effective against COVID-19. The Commission pursues intensive discussions with other vaccine manufacturers.
Ursula von der Leyen, President of the European Commission, yesterday said:
“The European Commission delivers on its promise to secure rapid access for Europeans and the world to a safe vaccine that protects us against the coronavirus. Each round of talks that we conclude with the pharmaceutical industry brings us closer to beating this virus. We will soon have an agreement with CureVac, the innovative European firm that received earlier EU funding to produce a vaccine in Europe. And our negotiations continue with other companies to find the technology that would protect us all“.
Stella Kyriakides, Commissioner for Health and Food Safety, yesterday said:
“Today we concluded talks with the European company CureVac to increase the chances of finding an effective coronavirus vaccine. We continue to work shoulder to shoulder with Member States and with vaccine developers to fulfil the aims of our European Vaccines Strategy - a vaccine for all.”
CureVac is a European company pioneering the development of a completely new class of vaccines based on messenger RNA (mRNA), transported into cells by lipid nanoparticles. The vaccine platform has been developed over the last decade. The basic principle is the use of this molecule as a data carrier for information, with the help of which the body itself can produce its own active substances to combat various diseases.
The exploratory talks concluded yesterday are intended to result in an Advance Purchase Agreement to be financed with the Emergency Support Instrument, which has funds dedicated to the creation of a portfolio of potential vaccines with different profiles and produced by different companies.
Latest News from
Updating the 2020 Industrial Strategy: towards a stronger Single Market for Europe's recovery06/05/2021 16:33:00
The Commission yesterday updated the EU Industrial Strategy to ensure that its industrial ambition takes full account of the new circumstances following the COVID-19 crisis and helps to drive the transformation to a more sustainable, digital, resilient and globally competitive economy.
Commission proposes new Regulation to address distortions caused by foreign subsidies in the Single Market *06/05/2021 15:25:00
The European Commission yesterday proposed a new instrument to address potential distortive effects of foreign subsidies in the Single Market.
European climate law: Council and Parliament reach provisional agreement06/05/2021 14:42:00
The Council's and the European Parliament's negotiators reached a provisional political agreement setting into law the objective of a climate-neutral EU by 2050, and a collective, net greenhouse gas emissions reduction target (emissions after deduction of removals) of at least 55% by 2030 compared to 1990.
President von der Leyen addresses the High Level Scientific Panel for the Global Health Summit06/05/2021 13:25:00
President von der Leyen yesterday addressed the High Level Scientific Panel for the Global Health Summit.
Speech by President von der Leyen at the State of the Union conference of the European University Institute06/05/2021 12:33:00
Speech given yesterday by President von der Leyen at the State of the Union conference of the European University Institute.
Recovery and Resilience Facility: Poland submits official recovery and resilience plan05/05/2021 09:25:00
The Commission has received an official recovery and resilience plan from Poland. This plan sets out the reforms and public investment projects that Poland plans to implement with the support of the Recovery and Resilience Facility (RRF).
Coronavirus: Commission proposes to ease restrictions on non-essential travel to the EU while addressing variants through new ‘emergency brake' mechanism04/05/2021 15:25:00
The Commission yesterday proposed that Member States ease the current restrictions on non-essential travel into the EU to take into account the progress of vaccination campaigns and developments in the epidemiological situation worldwide.
Recovery and Resilience Facility: Belgium, Italy, Austria, and Slovenia submit official recovery and resilience plans04/05/2021 13:25:00
The Commission has received official recovery and resilience plans from Belgium, Italy, Austria, and Slovenia.
European Health Union: Commission publishes open public consultation on the European Health Data Space04/05/2021 12:33:00
The Commission yesterday published an open public consultation on the European Health Data Space (EHDS) – an important building block of the European Health Union.